Search results for "Prostate Cancer"

showing 10 items of 413 documents

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

2019

Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Study aim: To evaluate the impact of a previous radical prostatectomy (RP) on the outcome of 223Ra therapy in mCRPC patients. The primary prostate tumor left untreated could progress during 223Ra treatment. Materials and methods: mCRPC symptomatic patients treated with 223Ra were enrolled. Luteinizing Hormone-Releasing Hormone analogue was maintained. No other anticancer therapy was given. 223Ra was administered i.v. at the dose of 55 kBq/kg every 4 weeks for 6 cycles. Patients were stratified according to previous RP or not. Hematological toxicity w…

Radium-223Malemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic AgentsBone NeoplasmsSettore MED/24 - UrologiaPrimary tumor03 medical and health sciencesProstate cancer0302 clinical medicineProstateRadium-222medicineHumansAgedProstatectomyRadiotherapybusiness.industryProstatectomyProstateChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadical prostatectomyPrimary tumorSurvival AnalysisRadiation therapyProstatic Neoplasms Castration-Resistantmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisConcomitantDisease ProgressionCastration resistant prostate cancerNeoplasm GradingRadiopharmaceuticalsbusinessmedicine.drugHormoneFollow-Up StudiesRadiumUrologic oncology
researchProduct

Using mRNA and small RNA gene expression changes in peripheral blood for easy detection of Ra-223 incorporation

2019

Radium-223Small RNARadiation analysisEnvironmental EngineeringmRNAlcsh:QR1-502Biologylcsh:Microbiologylcsh:PhysiologyIndustrial and Manufacturing EngineeringTranscriptomeProstate cancerRadium-223lcsh:ZoologyGene expressionmedicineradiation biomarkerssmall RNAincorporationlcsh:QL1-991Messenger RNAlcsh:QP1-981gene expression changesprostate cancermedicine.diseaseMolecular biologyPeripheral bloodtranscriptomemedicine.drugBIO Web of Conferences
researchProduct

Ra223 in bone metastases with osteolytic activity

2018

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development…

Radium-223lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyOsteolysislcsh:R895-920Case ReportScintigraphy030218 nuclear medicine & medical imagingradium 22303 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancerosteoblastic bone metastasesmedicineIn patientRadium-223 Dichlorideosteolytic bone metastasesmedicine.diagnostic_testbusiness.industryBone metastasesTherapeutic effectmedicine.disease030220 oncology & carcinogenesisRadiologybusinessmedicine.drugWorld Journal of Nuclear Medicine
researchProduct

Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience

2019

Background: Treatment with radium-223 has been shown to increase survival and to delay skeletal events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer (mCRPC). This treatment has also proved to be well tolerated, and hematological toxicity, in particular anemia, represents the most represented adverse event. Materials and methods: We evaluated the hematologic toxicity of Ra-223 treatment in a real-life experience of 38 patients from two Italian cancer centers, with bone metastases from mCRPC. The main endpoint of the study was the evaluation of the efficacy and tolerability of treatment with radium-223, with greater reference to hematological toxi…

Radium-223medicine.medical_specialtyAnemiaUrology030232 urology & nephrologyNeutropenialcsh:RC870-923Ra-22303 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineAdverse effectCancerToxicitybusiness.industryProstatemedicine.diseaselcsh:Diseases of the genitourinary system. UrologyDiscontinuationOlderTolerabilityDocetaxel030220 oncology & carcinogenesisOriginal Articlebusinessmedicine.drugProstate International
researchProduct

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chron…

2022

Guglielmo Mantica,1 Francesco Chierigo,1,2 Farzana Cassim,3 Francesca Ambrosini,1,2 Stefano Tappero,1,2 Rafaela Malinaric,1,2 Stefano Parodi,1,2 Andrea Benelli,4 Federico Dotta,4 Marco Ennas,4 Martina Beverini,1,2 Chiara Vaccaro,5 Salvatore Smelzo,6 Giovanni Guano,1,2 Federico Mariano,1,2 Calogero Paola,1,2 Giorgia Granelli,1,2 Virginia Varca,5 Carlo Introini,4 Salvatore Dioguardi,7 Alchiede Simonato,7 Andrea Gregori,8 Franco Gaboardi,6 Carlo Terrone,1,2 André Van der Merwe3 1IRCCS Ospedale Policlinico San Martino, U.O. Urologia, Genova, Italy; 2Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy; 3Department of Urology, Tygerberg Academic …

Research and Reports in UrologyaspirininflammationUrologyprostate-specific antigenprostate biopsyprostate cancer
researchProduct

In-depth proteomic analyses of expressed prostatic secretions in urine for identification of prostate-enriched proteins

2012

Settore BIO/13 - Biologia ApplicataProteomicprostate cancerEPS-urine
researchProduct

Ciprofloxacin Polymers Derived from Diallyltin and Divinyltin Dihalides

2008

The initial synthesis of condensation polymers from newly available divinyltin dichloride and diallyltin dichloride and ciprofloxacin is accomplished employing a modified interfacial polycondensation process. The polymeric (DP are about 2,000) products are rapidly (less than 15 seconds) formed in good yield. Infrared spectroscopy shows the formation of Sn-O and Sn-N bonds as predicted from the proposed structure. F-MALDI MS also shows ion fragments containing organotin in the predicted isotopic abundances as well as ion fragments containing both organotin and ciprofloxacin. The polymers exhibit low toxicity towards healthy WI-38 cells with variable toxicities towards a variety of cancer cel…

Settore CHIM/03 - Chimica Generale E InorganicaCiprofloxacin organotin organotin polymers diallyltin divinyltin F-MALDI MS organotin polyamine esters MALDI mass spectroscopy infrared spectroscopy colon cancerbone cancer prostate cancer pancreatic cancer
researchProduct

SEX STEROID METABOLISM AND ACTION, INFLAMMATION AND PROSTATE CANCER: HYPOTHETICAL MECHANISMS AND NETWORKS

2012

Settore MED/04 - Patologia GeneraleSEX STEROID; PROSTATE CANCER;SEX STEROIDPROSTATE CANCER
researchProduct

Role of TLR Polymorphisms in Aging and Age-Related Diseases

2017

Innate immunity provides the first line of host defense against infection by recognizing and killing microbes, and simultaneously activating an instructive immune response. Toll-like receptors (TLRs) are principal mediators of rapid microbial recognition, and they mainly function by detecting exogenous pathogen-associated molecular patterns. Recognition of their ligands actives signaling ways, which culminate in evocating acute host responses, involved in killing pathogens. Here, we describe the involvement of TLR4 polymorphisms in aging, and particularly in immunosenescence and age-related diseases, suggesting the crucial role of molecules of innate immunity in the pathophysiology of these…

Settore MED/04 - Patologia Generalebusiness.industryAge relatedImmunologySettore MED/05 - Patologia ClinicaMedicineTLR4 • Alzheimer’s disease • Prostate cancer • Diabetes • Atherosclerosis • Aneurysm • Longevitybusiness
researchProduct

Advances in immunotherapy of castration-resistant prostate cancer: Bisphosphonates, phosphoantigens and more.

2008

Settore MED/04 - Patologia Generaleprostate cancer bisphosphonates gamma delta T cells
researchProduct